When does this change take effect?

This change is effective Apr 1, 2026.

Medicare AdvantageCoverageMedium impact

MA08.021c, Dofetilide (Tikosyn®) Use in the Inpatient Setting

Q: Who is affected by this change?

This affects Independence Blue Cross Cardiology, Critical Care, Internal Medicine providers on Medicare Advantage plans.

Independence Blue Cross·Cardiology, Critical Care, Internal Medicine·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a reissued Medicare Advantage policy regarding Dofetilide (Tikosyn®) use in inpatient settings. The policy has been updated but specific changes are not detailed in the summary provided.

Action Required

Action needed

By April 1, 2026: Billing and clinical teams should review the full updated policy MA08.021c for any changes to coverage criteria or documentation requirements for Dofetilide (Tikosyn®) inpatient administration. Monitor for specific billing code or prior authorization changes when the complete policy details become available.

Related policy hubs

Independence Blue Cross policies Cardiology Critical Care Internal Medicine